Skip to main content

Cozadd Bruce C's Form 4 filing

Jazz Pharmaceuticals plc (JAZZ) · filed Apr 3, 2026

Accession no.
0001193210-26-000009
Filed
Apr 3, 2026
Trade date
Apr 1, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $1.14M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cozadd Bruce CCIK 0001193210Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 1, 2026Ordinary SharesSSaleDisposed−3,684$190.22F2−$700,770.48386,998Direct
Apr 1, 2026Ordinary SharesSSaleDisposed−2,292$190.94F3−$437,634.48384,706Direct
Apr 1, 2026Ordinary SharesSSaleDisposed−24$191.74−$4,601.76384,682Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.60 to $190.5603. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Referenced by the price of 1 transaction in Table I.

F3

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $190.6051 to $190.5982. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)